BMPR1B Human shRNA Plasmid Kit (Locus ID 658)
CAT#: TR320273
BMPR1B - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector
Product Images
![](https://cdn.origene.com/img/defaults-img.jpg)
Other products for "BMPR1B"
Specifications
Product Data | |
Locus ID | 658 |
Synonyms | ALK-6; ALK6; AMDD; BDA1D; BDA2; CDw293 |
Vector | pRS |
E. coli Selection | Ampicillin |
Mammalian Cell Selection | Puromycin |
Format | Retroviral plasmids |
Kit Components | BMPR1B - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = 658). 5µg purified plasmid DNA per constructNon-effective 29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free. |
RefSeq | NM_001203, NM_001256792, NM_001256793, NM_001256794, BC069796, BC047773, BC069803 |
Summary | 'This gene encodes a member of the bone morphogenetic protein (BMP) receptor family of transmembrane serine/threonine kinases. The ligands of this receptor are BMPs, which are members of the TGF-beta superfamily. BMPs are involved in endochondral bone formation and embryogenesis. These proteins transduce their signals through the formation of heteromeric complexes of 2 different types of serine (threonine) kinase receptors: type I receptors of about 50-55 kD and type II receptors of about 70-80 kD. Type II receptors bind ligands in the absence of type I receptors, but they require their respective type I receptors for signaling, whereas type I receptors require their respective type II receptors for ligand binding. Mutations in this gene have been associated with primary pulmonary hypertension. Several transcript variants encoding two different isoforms have been found for this gene. [provided by RefSeq, Feb 2012]' |
shRNA Design | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, align it with our published shRNA design sequences. If these do not align, please utilize our custom shRNA service |
Performance Guaranteed | OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred). |
Documents
Product Manuals |
FAQs |
Resources
RNAi Resources |
{0} Product Review(s)
0 Product Review(s)
Submit review
Be the first one to submit a review
Product Citations
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen
complexities in the preparation of your product. International customers may expect an additional 1-2 weeks
in shipping.